Everlywell to roll out home testing kits for COVID-19

March 19, 2020
Digital Transformation More...
by Danielle Bradnan
Truly disruptive

Everlywell has developed a kit for COVID-19 and will launch on March 23, 2020. This is extremely important because it allows the scientific community to get the numbers needed to effectively plan response strategies for the next 18 months – the expected timeline for vaccine distribution. Right now, due to limited access to tests, scientists and policymakers are dealing with a lot of unknowns, including the number of actual cases – as a dearth of tests means many with symptoms are simply asked to stay home to minimize the spread. Everlywell has developed a plan to support a testing capacity of a 250,000 tests per week, which means a greater availability of data, which will in turn inform the next steps in managing this pandemic.

For the original news article, click here .

Further Reading

Clear Labs strikes partnership with Oxford Nanopore Technologies for its food safety testing solution

News Commentary | March 27, 2019

By incorporating Oxford Nanopore's long‑read sequencing technology, Clear Labs claims it can now achieve 99.99% accuracy in identifying pathogen absence or presence. Furthermore, Clear Labs revealed its turnaround time currently stands at 24 hours – certainly an improvement over the "gold standard" ... Not part of subscription

Viome demonstrates link between gut microbiome and blood sugar response

News Commentary | July 04, 2019

At a high level, the findings are exactly the same as those from DayTwo, but the main difference is that Viome employed metatranscriptomic sequencing. Through this research, our perception of the company is improving. On the technology front, our two key concerns have been 1) its ability to maintain... To read more, click here.

Abbott launches five-minute test for COVID-19

News Commentary | March 30, 2020

The test has received Emergency Use Authorization from the U.S. FDA and is extremely useful to expedite the testing process. The test, however, relies on large amounts of genomic material to be present, which doesn't happen in the early stages of the infection. Clients should also monitor for tech ... Not part of subscription